View : 20 Download: 0

Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: The practical evidence of antidiabetic monotherapy study

Title
Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: The practical evidence of antidiabetic monotherapy study
Authors
Yoon K.H.Shin J.A.Kwon H.S.Lee S.H.Min K.W.Ahn Y.B.Yoo S.J.Ahn K.J.Park S.W.Lee K.W.Sung Y.A.Park T.S.Kim M.S.Kim Y.K.Nam M.S.Kim H.S.Park I.B.Park J.S.Woo J.T.Son H.Y.
Ewha Authors
성연아
SCOPUS Author ID
성연아scopus
Issue Date
2011
Journal Title
Diabetes and Metabolism Journal
ISSN
2233-6079JCR Link
Citation
vol. 35, no. 1, pp. 26 - 33
Indexed
SCOPUS; KCI scopus
Abstract
Background: Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. Methods: We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels. Results: HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group. Conclusion: The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information. © 2011 Korean Diabetes Association.
DOI
10.4093/dmj.2011.35.1.26
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE